Literature DB >> 11699811

Summary of the practice parameter for the use of stimulant medications in the treatment of children, adolescents, and adults.

L L Greenhill, S Pliszka, M K Dulcan, W Bernet, V Arnold, J Beitchman, R S Benson, O Bukstein, J Kinlan, J McClellan, D Rue, J A Shaw, S Stock, K Kroeger.   

Abstract

This practice parameter describes treatment with stimulant medication. It uses an evidence-based medicine approach derived from a detailed literature review and expert consultation. Stimulant medications in clinical use include methylphenidate, dextroamphetamine, mixed salts of amphetamine, and pemoline. They carry U.S. Food and Drug Administration indications for the treatment of attention-deficit hyperactivity disorder.

Entities:  

Mesh：

Substances：

Year:  2001        PMID： 11699811     DOI： 10.1097/00004583-200111000-00020

Source DB:  PubMed          Journal:  J Am Acad Child Adolesc Psychiatry        ISSN： 0890-8567            Impact factor:   8.829


  17 in total

Review 1.  Achieving remission as a routine goal of pharmacotherapy in attention-deficit hyperactivity disorder.

Authors:  J Antoni Ramos-Quiroga; Miguel Casas
Journal:  CNS Drugs       Date:  2011-01       Impact factor: 5.749

2.  Using Meta-analysis to Compare the Efficacy of Medications for Attention-Deficit/Hyperactivity Disorder in Youths.

Authors:  Stephen V Faraone
Journal:  P T       Date:  2009-12

3.  Steady-state bioavailability of extended-release methylphenidate (MPH-MLR) capsule vs. immediate-release methylphenidate tablets in healthy adult volunteers.

Authors:  Akwete Adjei; Robert J Kupper; Nathan S Teuscher; Sharon Wigal; Floyd Sallee; Ann Childress; Scott H Kollins; Laurence Greenhill
Journal:  Clin Drug Investig       Date:  2014-11       Impact factor: 2.859

4.  A randomized, double-blind, cross-over, phase IV trial of oros-methylphenidate (CONCERTA(®)) and generic novo-methylphenidate ER-C (NOVO-generic).

Authors:  Angelo Fallu; Farida Dabouz; Melissa Furtado; Leena Anand; Martin A Katzman
Journal:  Ther Adv Psychopharmacol       Date:  2016-05-01

5.  Comparison of the efficacy of two different modified release methylphenidate preparations for children and adolescents with attention-deficit/hyperactivity disorder in a natural setting: comparison of the efficacy of Medikinet(®) retard and Concerta(®)--a randomized, controlled, double-blind multicenter clinical crossover trial.

Authors:  Manfred Döpfner; Claudia Ose; Roland Fischer; Richard Ammer; André Scherag
Journal:  J Child Adolesc Psychopharmacol       Date:  2011-07-26       Impact factor: 2.576

Review 6.  Assessment and management of attention-deficit hyperactivity disorder in adults.

Authors:  Margaret Weiss; Candice Murray
Journal:  CMAJ       Date:  2003-03-18       Impact factor: 8.262

7.  Assessment of physician practices in adult attention-deficit/hyperactivity disorder.

Authors:  David W Goodman; Craig Bruce Surman; Priscilla B Scherer; Gregory D Salinas; Jennifer J Brown
Journal:  Prim Care Companion CNS Disord       Date:  2012-08-02

8.  Comparing the efficacy of stimulants for ADHD in children and adolescents using meta-analysis.

Authors:  Stephen V Faraone; Jan Buitelaar
Journal:  Eur Child Adolesc Psychiatry       Date:  2009-09-10       Impact factor: 4.785

9.  Impaired transcallosally mediated motor inhibition in adults with attention-deficit/hyperactivity disorder is modulated by methylphenidate.

Authors:  Jacqueline Hoeppner; Roland Wandschneider; Martin Neumeyer; Wolfgang Gierow; Frank Haessler; Sabine C Herpertz; Johannes Buchmann
Journal:  J Neural Transm (Vienna)       Date:  2008-01-15       Impact factor: 3.575

10.  Safety and tolerability of flexible dosages of prolonged-release OROS methylphenidate in adults with attention-deficit/hyperactivity disorder.

Authors:  Jan K Buitelaar; J Antoni Ramos-Quiroga; Miguel Casas; J J Sandra Kooij; Asko Niemelä; Eric Konofal; Joachim Dejonckheere; Bradford H Challis; Rossella Medori
Journal:  Neuropsychiatr Dis Treat       Date:  2009-09-15       Impact factor: 2.570
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.